Gene-IT Licenses GenomeQuest™ to Canadian Intellectual Property Office
News Sep 22, 2005
Gene-IT has announced that it has signed an agreement to license its flagship GenomeQuest™ offering to the Canadian Intellectual Property Office (CIPO).
GenomeQuest is a genomic information service and software application that is designed to provide sequence comparison solutions for biological and patent investigators.
With CIPO's increased recognition as an international intellectual property (IP) search authority, the organization's ability to provide up-to-the-minute, accurate information becomes even more important.
GenomeQuest will enable CIPO's biotech examiners to participate in searching the most recent patent records using both biological and IP-sensitive search methods.
The terms of the agreement call for Gene-IT to provide access to GenomeQuest services for all IP examiners in CIPO's biotech practice.
GenomeQuest is designed to enable users to perform simultaneous, large-scale genomic and proteomic sequence comparisons, and rapidly obtain a structured presentation of the best-fit answers drawn from the up-to-date sources of global patent information.
Ron Ranauro, CEO of Gene-IT, said, "We are very pleased to be selected as the IP search solution for the Canadian Intellectual Property Office.”
“The adoption of our offering by a growing number of issuing patent authorities is a major endorsement of GenomeQuest.”
“We are delighted to provide CIPO's biotech IP examiners with its capabilities."
GenomeQuest is designed to provide automated search capability and context-sensitive views of sequence information.
The system couples sequence retrieval with sequence comparison for inter- and cross-species comparison of up-to-date biological and patent reference data.
End-users initiate questions by retrieving sequence records using text identifiers, gene names, patent numbers and other keywords, and immediately cross-compare them with new information contained in and linked to sequence alignments.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE